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MF population in urine, the CD161 Mo population was negli-Detection of urinary macrophages expressing the CD16
gible in peripheral blood. Immunohistochemically, CD161(FcgRIII) molecule: A novel marker of acute inflammatory
glomerular injury. MF were present in the glomeruli of active proliferative glo-
Background. The CD16 antigen is the Fcg receptor III. merulonephritis, whereas such cells were absent in inactive
CD141CD161 cells are proinflammatory monocytes/macro- proliferative glomerulonephritis or nonproliferative glomeru-
phages (Mo/MF) that constitute a minor population in the lar diseases.
peripheral blood of healthy individuals. Little is known about Conclusion. CD161 MF may be effector cells involved in
the expression of CD16 antigen on Mo/MF in glomerulone- the acute inflammation common to all types of proliferative
phritis. glomerulonephritis. Furthermore, the detection of CD161 MF
Methods. Flow cytometric analyses were performed on urine
in urine, as well as urinary MF counts, may serve as a usefuland blood samples obtained from 209 patients with various
indicator of the active stage of proliferative glomerulonephritis.renal diseases. Patients variously suffered from rapidly progres-
sive crescentic glomerulonephritis (RPGN), membranoprolif-
erative glomerulonephritis (MPGN), postinfectious acute glo-
merulonephritis (AGN), Henoch-Scho¨nlein purpura nephritis
(HSPN), IgA nephropathy (IgAN), membranous nephropathy
Macrophages (MF) are readily identified in the glo-(MN), minimal change nephrotic syndrome (MCNS), lupus
merulus in most forms of proliferative glomerulonephri-nephritis (LN), acute interstitial nephritis, hereditary nephrop-
athy, idiopathic renal hematuria (IRH), and renal stone. tis, particularly rapidly progressive glomerulonephritis.
Results. The CD161 MF population of cells was present Flow cytometry (FCM) is a powerful tool for preciselyin the urine of hematuria-positive patients with proliferative
examining the characteristics of cells, including mononu-glomerulonephritis, including AGN, IgAN, RPGN, MPGN,
and LN with acute inflammatory lesions, such as endocapillary clear cells in the urine of patients with proliferative glo-
proliferation, tuft necrosis, and cellular crescents. In contrast, merulonephritis. Unlike examination by renal biopsy,
the urinary CD161 MF population was negligible in hematu-
this method is noninvasive and thus facilitates serial ex-ria-positive patients with nonproliferative renal disease, includ-
amination. Using FCM, we previously found and re-ing hereditary nephropathy, IRH, and renal stone and also
in patients with proliferative glomerulonephritis lacking acute ported that the magnitude of urinary MF excretion is
inflammatory lesions. Total urinary MF of these patients were significantly correlated with the extent of crescentic le-
much less than those of patients having proliferative glomerulo-
sions in biopsy specimens [1, 2]. In the course of a pheno-nephritis with acute inflammatory lesions. Transient expansion
of the CD161 MF population in urine was observed during typical analysis of urinary MF using FCM, we found that
the acute exacerbation of urinary abnormalities, whereas the there was a urinary MF subset that expressed CD16
disappearance of CD161 MF closely preceded the ameliora- antigen (a human natural killer cell antigen) [3] in certaintion of urinary abnormalities in patients with proliferative glo-
patients. The CD161 Mo is regarded as a proinflamma-merulonephritis. In 38 of the 98 patients positive for CD161
tory monocyte (Mo), and the CD161 Mo population is
increased in the peripheral blood of patients suffering
Key words: glomerulonephritis, inflammation, flow cytometry, necro-
from disorders such as sepsis [3] and malignancy [4]. Thesis, cellular crescents.
purpose of this study was to clarify the possible clinical
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METHODS indicating cell-structure; FITC; and PE. The selection of
cells for fluorescence analysis was performed within aPatients and urine samples
scattergram using Paint-A-Gate (Becton Dickinson)
Peripheral blood and freshly voided urine samples (50 software, providing an objective means of excluding de-
to 100 ml) were obtained from 20 healthy individuals bris and other cells from the lymphocyte and monocyte
and 204 patients with various types of glomerular disease: gate [2]. Briefly, the localization of CD31 and CD141
IgA nephropathy (IgAN, N 5 94), Henoch-Scho¨nlein cells in the scattergram (FSC vs. SSC) was optimized
purpura nephritis (HSPN, N 5 10), idiopathic renal he- using the Paint-A-Gate program. Then the gate was set
maturia (IRH, histologically confirmed as “isolated C3 on the cells in which these two cell subpopulations were
deposition disease,” N 5 17) [2], crescentic rapidly pro- included. The percentage and number of a specific leuko-
gressive glomerulonephritis (RPGN, N 5 17), membra- cyte subset were determined by two-color FCM. In a
noproliferative glomerulonephritis (MPGN, N 5 9), two-color analysis of urine samples with the combination
lupus nephritis (LN, N 5 11), postinfectious acute glo- of anti-CD14 and anti-CD16 antibodies, when the
merulonephritis (AGN, N 5 16), minimal change ne- CD161 MF subset was present, a part of the CD161
phrotic syndrome (MCNS, N 5 7), membranous ne- MF overlapped the cluster of cell debris, which made it
phropathy (MN, N 5 9), hereditary nephropathy (N 5 difficult to accurately count the number of CD161 MF
9), and acute interstitial nephritis (AIN, N 5 5). Urine in the cytogram (Fig. 1). Thus, in the FCM analyses for
samples were also obtained from five patients with kid- urine, the presence of CD161 MF was defined when
ney stones exhibiting macroscopic hematuria. In 15 pa- the cluster of CD161 MF, usually partly overlapping
tients with MPGN, crescentic IgAN, RPGN, HSPN, and the cluster of cell debris, was present on a two-color
LN, serial FCM analyses were performed. In addition, cytogram. In addition, quantitative MF concentrations
urine samples were obtained serially from five patients in urine were determined by two-color FCM analysis,
with IgAN both in the clinical quiescence phase and with the combination of anti-CD14 and anti-CD3 anti-
acute exacerbation phase following pharyngitis. bodies as described previously [2].
The definition of “active stage” in this study was basedFlow cytometric analysis
on the presence of acute inflammatory lesions, such as
Urine samples were centrifuged for 10 minutes at 1500 cellular crescent, tuft necrosis, and/or endocapillary pro-
r.p.m. The sediment was washed three times in phos- liferation in the biopsy specimens.
phate-buffered saline (PBS) and was resuspended. The
Immunohistochemical studyviability of the mononuclear cells in urine was 95 to 99%
by Trypan blue dye exclusion. Fifty microliters of the Kidney biopsy specimens from various forms of glo-
cell suspensions were transferred to small test tubes. Ten merulonephritis (IgAN with active lesions, N 5 7; IgAN
microliters of green (FITC)-labeled or red (PE)-labeled without active lesions, N 5 7; RPGN, N 5 3; MPGN,
monoclonal antibody were added, and the suspension N 5 4; LN, N 5 3; MN, N 5 7; MCNS, N 5 4; hereditary
was gently mixed and incubated at 48C for 30 minutes. nephropathy, N 5 3) were assessed by immnohistochem-
After incubation, the cells were washed twice in PBS. ical study. Specimens for the immunohistochemical study
Then 1 ml of IMMUNO-LYSE solution (Coulter, Hia- were fixed in periodate-lysine-2% paraformaldehyde at
leah, FL, USA) was added to each tube for hemolysis. 48C for six hours and were washed in PBS containing
After the tubes had been allowed to sit for 30 seconds, increasing concentrations of sucrose. Then they were
150 ml of fixative (Coulter) was added. The cells were embedded in OCT compound (Miles Pharmaceutical,
then washed three times with 3 ml of PBS and were Napervill, IL, USA) and were rapidly frozen. Frozen
analyzed by FCM. The combinations of antibodies used sections (4 mm thick) were cut in a cryostat and overlaid
were FITC-labeled anti-CD14 (Leu M3, mouse IgG2b; onto egg albumin-coated glass slides. Histofine kit (Ni-
macrophages/monocytes; Becton Dickinson, San Jose, chirei, Tokyo, Japan) was used for the immunohisto-
CA, USA) and PE-labeled anti-CD16 (Leu 11c, mouse chemical study. Briefly, the procedure involved succes-
IgG1; IgG Fc receptor III; Becton Dickinson), or PE- sive incubation with the primary antibody (3G8/FcgRIII
labeled anti-CD3 (Leu 4, mouse IgG1; Pan T cells; Bec- Coulter, diluted at 1:50) for 12 hours at 48C. Endogenous
ton Dickinson). Simultest Control (IgG1-FITC 1 IgG2a- peroxidase was inactivated by incubation with 100%
PE; Becton Dickinson) was used as a negative control. methanol containing 0.3% hydrogen peroxide. After be-
The flow cytometric analysis was carried on a FAC- ing washed with PBS and incubated in Streptavidin en-
Scan (Becton Dickinson). Twenty thousand cells were zyme conjugated for 30 minutes at room temperature,
analyzed in each sample. Consort 30 (Becton Dickinson) the reaction products were visualized by incubation with
software was used to analyze the data. For each cell, 0.025% diaminobenzidine (DAB) solution containing
four parameters were measured simultaneously: forward 0.01 m sodium azide and 0.006% hydrogen peroxide and
counter stained with methyl green.scatter (FSC), indicating cell-volume; side scatter (SSC),
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Fig. 1. Two-color flow cytometric analysis of
urinary mononuclear cells of a patient with
rapidly progressive crescentic glomerulone-
phritis (RPGN). CD161 MF were present in
the urine (arrow). In two-color flow cytomet-
ric analysis using anti-CD141 and anti-CD31
antibody, there was no double-positive cell
population.
To obtain precise information about infiltrating were detected. CD16 antigen expression was marked on
urinary MF in most patients with RPGN and AGN,CD161 cells in the glomerulus, we used immunoelectron
microscopy sections according to the method described whereas the expression of CD16 antigen on urinary MF
was negligible in patients with IRH, hereditary N, MN,previously [5]. Briefly, cryostat sections adjacent to those
MCNS, or renal stones. In IgAN, HSPN, MPGN, andtaken for light microscopy were treated by the indirect
LN patients, the CD161 MF were present in those hav-immunoperoxidase method. After incubation with the
ing acute inflammatory lesions such as endocapillary pro-first antibody for 24 hours at 48C, the sections were
liferation, cellular crescents, and/or necrotizing lesions.combined with F(ab)2 fragments of goat antimouse IgG
In contrast, CD161 MF were negligible in patients with-labeled with horseradish peroxidase (diluted at 1: 100 in
out such active lesions (Fig. 2).PBS; Amersham Japan Co., Tokyo, Japan) overnight
for the second antibody. The sections were fixed in 1%
Expression of CD16 antigen on monocytes inglutaraldehyde for 20 minutes at room temperature.
peripheral bloodAfter washing, they were incubated with 0.025% DAB
solution containing 0.006% hydrogen peroxide for two to In normal subjects, CD16 antigen was only rarely ex-
five minutes. They were then post-fixed with 2% osmium pressed on monocytes (Mo) in peripheral blood (ranged
tetroxide for 45 minutes at room temperature, dehy- from 0 to 8% of the entire Mo population). In patients
drated in graded ethanol, and embedded in Epon. Ultra- with primary renal parenchymal disease, there was a
thin sections were examined with an electron microscope. significant increase in the proportion of CD161 Mo. A
total of 12 of 17 patients with RPGN, 6 of 9 with MPGN,
38 of 94 with IgAN, 4 of 10 with HSPN, and 9 of 19 with
RESULTS
AGN showed a significant increase in the proportion of
Expression of CD16 antigen on urinary macrophages CD161 Mo (more than 10% of the entire Mo popula-
tion). In all six patients with AGN in whom the FCMIn normal subjects and hematuria-negative patients,
urinary MF counts were negligible, and no CD161 MF analysis was carried out within 10 days after the clinical
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Fig. 2. Two-color flow cytometric analysis of urinary mononuclear cells obtained from patients with various renal diseases. CD161 MF are present
in urine during the active phase of proliferative glomerulonephritis, regardless of the disease type (arrow). There are no CD161 MF in the urine
of patients with nonproliferative glomerular diseases and renal stone. Abbreviations are: AGN, postinfectious acute glomerulonephritis; IgAN, IgA
nephropathy; IRH, idiopathic renal hematuria; MPGN, membranoproliferative glomerulonephritis; RPGN, rapidly progressive glomerulonephritis.
onset, both urinary CD161 MF and an increased in the clinical quiescence phase, whereas the cluster of
CD161 Mo population in peripheral blood were ob- CD161 MF transiently appeared concomitantly with a
served. Among patients with nonproliferative glomerul- marked increase in the total MF counts in the urine in
opathy, 4 of 9 with MN exhibited increases in the propor- the acute exacerbation phase (Fig. 4).
tion of CD161 Mo. In contrast, in patients with MCNS, The proportion of CD161 MF in the urine of patients
IRH, and hereditary nephropathy, there were no signifi- with crescentic IgAN, HSPN, RPGN, MPGN, and LN
cant increases in the proportion of the CD161 Mo, ex- diminished remarkably in most of the cases, concomitant
cept for one patient with hereditary nephropathy. In with the decline in urinary total MF counts in response
approximately 40% (38/98) of the patients who exhibited to steroid therapy (Fig. 5). Again, the disappearance of
a CD161 MF population in urine, the percentage of CD161 MF closely preceded the amelioration of urinary
CD161 Mo in peripheral blood was within normal levels abnormalities.
(Table 1). None of these patients with elevated CD161
Mo in peripheral blood had any signs of sepsis or clini- Immunohistochemical study
cally detectable infectious disease. At the time of exami-
CD161 cells were virtually absent in biopsy specimensnation, none of the 16 patients with AGN had persistent
of nonproliferative glomerular diseases, including MN,symptoms of preceding infection, such as acute tonsillitis.
MCNS and hereditary nephropathy and IgAN without
active lesions. In contrast, in 12 of 17 patients with prolif-The clinical setting and CD161 Mo/MF
erative glomerulonephritis in the active stage, CD161In patients with AGN, both CD161 Mo in peripheral
cells were found to be present in the glomerulus (up toblood and CD161 MF in the urine disappeared with
7 positive cells per glomerulus). The glomerular CD161the amelioration of glomerulonephritis, and the disap-
cells often showed a polymorphonuclear appearance,pearance of CD161 MF and decrease in urinary MF
suggesting that a considerable proportion of thesecounts closely preceded the amelioration of urinary ab-
CD161 cells were neutrophils, not MF.normalities (Fig. 3). In five IgAN patients, urine FCM
Immunoelectron microscopic study showed thatanalyses were carried out both in the clinical quiescence
CD161 MF were present in the glomerular tufts of pro-phase and transient acute exacerbation phase following
pharyngitis. CD161 MF were negligible in the urine liferative GN (Fig. 6).
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Table 1. Incidence of CD161MoMF in various renal diseases
U-CD161MF-positive U-CD161MF-negative
N PBMo $ 10% ,10% PBMo $ 10% ,10%
AGN
time after onset
#10 days 6 6 (100%) 0 0 0
.10 days 10 3 (30%) 6 (60%) 0 1 (10%)
RPGN 17 11 (65%) 4 (24%) 1 (6%) 1 (6%)
HSPN 10 2 (20%) 3 (30%) 2 (20%) 3 (30%)
IgAN 94 28 (30%) 21 (22%) 10 (11%) 35 (37%)
LN 11 3 (27%) 2 (18%) 3 (27%) 3 (27%)
MPGN 9 6 (67%) 2 (22%) 0 1 (11%)
AIN 5 1 (20%) 0 3 (60%) 1 (20%)
MN 9 0 0 4 (44%) 5 (56%)
Hereditary nephropathy 9 0 0 1 (11%) 8 (89%)
IRH 17 0 0 0 17 (100%)
MCNS 7 0 0 0 7 (100%)
Renal stone 5 0 0 0 5 (100%)
Abbreviations are in the Appendix.
Fig. 3. Serial changes in CD161 Mo/MF in a patient with AGN. Both urinary CD161 MF and CD161 Mo in peripheral blood disappear with
the amelioration of glomerulonephritis.
DISCUSSION an important role in phagocytosis [9, 10]. Recently, how-
ever, CD16 has also been found on a small subset ofThe CD16 antigen has been shown to be the low-
circulating monocytes that make up less than 10% ofaffinity IgG receptor, FcgRIII, originally identified on
the total Mo population or approximately 1% of all whitenatural killer cells and granulocytes [6, 7]. In the mono-
blood cells [11, 12]. CD161 Mo have been found to becytic lineage, CD16 was initially believed to be restricted
to a subset of mature MF [8], where it apparently plays increased in clinical settings of bacterial sepsis [3], human
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Fig. 4. Serial changes in CD161 MF and MF counts in patients with
IgAN. A transient expansion of the CD161 MF accompanied by
an increase in the total number of urinary MF is observed in acute
exacerbation phase. Symbols are: (s) CD161 MF-absent; (d) CD161 Fig. 5. Serial changes in CD161 MF and MF counts in a patient
MF-present. with active glomerulonephritis treated with steroid therapy. The
CD161 MF population is lost accompanied by a decrease in total
urinary MF counts. Symbols are: (s) CD161 MF-absent, (d) CD161
MF-present.
immunodeficiency virus infection [13], and malignancy
[4]. Experimentally, a marked increase in the number of
CD161 Mo was observed following the administration of cent studies have suggested a role for Hemophilus para-
recombinant human MF colony-stimulating factor [4, 14]. influenzae as a pathogen of IgAN [17, 18], although clinical
Our study showed that CD161 Mo are elevated in the symptoms related to this pathogen are rarely observed.
peripheral blood of patients with a variety of glomerular Experimentally, bacterial lipopolysaccharide (LPS) en-
diseases. As there were no clinical signs of systemic bac- hances CD16 expression on Mo [19]. The mammalian
terial or viral infection and no evidence of malignancies, host is continually exposed to environmental indigenous
the patients who exhibited elevated CD161 Mo in pe- microflora and associated LPS.
ripheral blood in this study differed clinically from those As the CD16 antigen is expressed not only on activated
previously reported. The mechanisms underlying the in- Mo/MF but also on granulocytes and natural killer cells,
crease in CD161 Mo in certain glomerulonephritis pa- granulocytes are likely to be the major subset of CD161
tients have yet to be elucidated. However, we hypothesize cells in urinary sediments. Thus, it is practically difficult
that subclinical, in some cases nephritogenic, bacterial to recognize CD161 MF in urinary sediments by using
or viral infection may be involved. In fact, all patients conventional immunocytostaining methods under light
with postinfectious glomerulonephritis in the early stage microscopy. FCM analysis therefore may be a more reli-
(within 10 days after the clinical onset) had a significant able method for the detection of urinary CD161 MF.
increase in CD161 Mo population, and this Mo subset Increased CD161 MF levels in urine were observed
subsequently disappeared from both urine and periph- in a majority of patients with proliferative glomerulone-
eral blood concurrently with the amelioration of glomer- phritis in the active stage, but in none of the patients
ulonephritis. Moreover, chronic tonsillitis is a common with nonproliferative glomerular or urological diseases.
finding in patients with IgAN, and the therapeutic effec- Thus, the exposure of MF to the urine itself probably
does not cause the conversion from CD16– MF totiveness of tonsillectomy has been reported [15, 16]. Re-
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munoglobulin deposition in the glomeruli, CD161 MF-
related tissue injury is a common event that occurs in
the active stage of glomerulonephritis.
Although the functional role of CD161 Mo/MF in
proliferative glomerulonephritis has yet to be deter-
mined, a recent study demonstrated that CD161 Mo
produced high levels of proinflammatory cytokines such
as tumor necrosis factor, whereas the anti-inflammatory
cytokines such as interleukin-10 are produced at low
levels or are absent, suggesting that these cells may func-
tion as efficient immunostimulatory and proinflamma-
tory Mo/MF [19]. Thus, it is conceivable that CD161
MF act as proinflammatory cells that trigger an inflam-
matory immune response in the glomeruli. Furthermore,
it has been reported that CD161 MF are cytotoxic to
malignant target cells [20, 21]. Whether CD161 MF
have such cytotoxic effects on nontransformed glomeru-
lar cells must be determined in future studies. FromFig. 6. Immunoelectron micrograph of renal biopsy of a patient with
MPGN. CD161 MF is present in the glomerular lumen (arrowheads; the clinical viewpoint, our study raises the promising
original magnification 33000). possibility that the detection of a CD161 MF population
in urine in combination with total urinary MF counts
using FCM is a useful noninvasive strategy for detecting
active proliferative glomerulonephritis.CD161 MF, because if this were the case, nonprolifera-
tive disease should also exhibit an increase. It is assumed
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The presence of a CD161 MF population, as well
Abbreviations used in this article are: AGN, postinfectious acuteas the increase in total MF counts in urine, was well glomerulonephritis; AIN, acute interstitial nephritis; FCM, flow cytom-
correlated with the level of severity of acute inflamma- etry; HSPN, Henoch-Scho¨nlein purpura nephritis; IgAN, IgA nephrop-
athy; IRH, idiopathic renal hematuria; LN, lupus nephritis; MCNS,tion in the glomeruli. Both the disappearance of the
minimal change nephrotic syndrome; MN, membranous nephropathy;CD161 MF with a decrease in total MF counts in the Mo, monocytes; MF, macrophages; MPGN, membranoproliferative
urine and the amelioration of the urinary abnormalities glomerulonephritis; RPGN, rapidly progressive crescentic glomerulo-
nephritis.were brought about with steroid therapy in RPGN,
HSPN, LN, and IgAN patients, whereas CD161 MF
REFERENCESdisappeared concurrently with the amelioration of glo-
merulonephritis in patients with AGN. Furthermore, 1. Hotta O, Yusa N, Ooyama M, Taguma Y: Urinary macrophage
counts and ratio to T lymphocytes: Possible use in differentialCD161 MF were detected only in glomeruli in the active
diagnosis and management of glomerular disease. J Clin Lab Anal
phase of proliferative glomerulonephritis and were ab- 10:205–208, 1996
2. Hotta O, Taguma Y, Yusa N, Ooyama M: Analysis of mononu-sent in the inactive phase.
clear cells in urine using flow cytometry in glomerular diseases.These findings strongly suggest that excretion of
Kidney Int 46(Suppl 47):S117–S121, 1994
CD161 MF may reflect the involvement of CD161 MF 3. Fingerle G, Pforte A, Passlick B, Blumenstein M, Strobel M,
Ziegler-Heitbrock HWL: The novel subset of CD141/CD161in the development of active proliferative glomerular
blood monocytes expanded in sepsis patients. Blood 82:3170–3176,lesions such as cellular crescents, tuft necrosis, and/or 1993
endocapillary proliferation, regardless of the type of glo- 4. Saleh MN, Goldman SJ, Lobuglio AF, Beall AC, Sabio H,
McCord MC, Minasian L, Alpaugh K, Weiner LM, Munn D:merulonephritis. In other words, in many types of prolif-
CD161 monocytes in patients with cancer: Spontaneous elevationerative glomerulonephritis, including RPGN, IgAN, and pharmacologic induction by recombinant human macrophage
colony-stimulating factor. Blood 85:2910–2917, 1995MPGN, AGN, and LN, regardless of the pattern of im-
Hotta et al: CD161 macrophages in urine1934
5. Hotta O, Yusa Y, Furuta T, Onodera S, Kitamura H, Taguma JV, Glaspy JA: Alterations in phenotype and cell-surface antigen
expression levels of human monocytes: Differential response to inY: Membranoproliferative glomerulonephritis in the aged and its
possible causal relationship with CD81CD571 lymphocytes. Clin vivo administration of rhM-CSF or rhGM-CSF. Cytometry 22:103–
110, 1995Nephrol 49:138–144, 1998
6. Perussia B, Starr S, Abraham S, Fanning V, Trinchieri G: Hu- 15. Lagrue G, Sadrux T, Laurent J, Hirbec G: Is there a treatment
of mesangial IgA glomerulonephritis? (letter) Clin Nephrol 16:161,man natural killer cells analyzed by B73.1, a monoclonal antibody
blocking Fc receptor functions. I. Characterization of the lympho- 1981
16. Be´ne´ MC, Hurault de Ligny B, Kessler M, Foliguet B, Faurecyte subset reactive with B73.1. J Immunol 130:2133–2141, 1983
7. Unkeless J: Function and heterogeneity of human Fc receptors GC: Tonsils in IgA nephropathy. Contrib Nephrol 104:153–161,
1993for immunoglobulin G. J Clin Invest 83:355–361, 1988
8. Clarkson SB, Ory PA: Developmentally regulated IgG Fc recep- 17. Suzuki S, Nakatomi Y, Sato H, Tsukada H, Arakawa M: Haemo-
philus parainfluenzae antigen and antibody in renal biopsies andtors on cultured human monocytes. J Exp Med 167:408–420, 1988
9. Munn DH, McBride M, Cheung NKV: Role of low-affinity Fc serum of patients with IgA nephropathy. Lancet 343:12–16, 1994
18. Suzuki S, Gejyo F, Nakatomi Y, Odani S, Sato H, Arakawareceptors in antibody-dependent tumor cell phagocytosis by mono-
cyte-derived macrophages. Cancer Res 51:1117–1123, 1991 M: Role of IgA, IgG, and IgM antibodies against Haemophilus
parainfluenzae antigens in IgA nephropathy. Clin Nephrol 46:287–10. Takai T, Li M, Sylvestre D, Clynes R, Ravetch JV: FcR gamma
chain deletion results in pleiotropic effector cell defects. Cell 76:519– 295, 1996
19. Frankenberger M, Sternsdorf T, Pechumer H, Pforte A,529, 1994
11. Passlick B, Flieger D, Ziegler-Heitbrock HWL: Identification Ziegler-Heitbrock HWL: Differential cytokine expression in hu-
man blood monocyte subpopulations: A polymerase chain reactionand characterization of novel monocyte subpopulation in human
peripheral blood. Blood 74:2527–2534, 1989 analysis. Blood 87:373–377, 1996
20. van Ravenswaay Claasen HH, Kluin PM, Fleuren GJ: Tumor12. Ziegler-Heitbrock HWL, Strobel M, Kipper D, Fingerle G,
Schlunck T, Petersmann I, Ellwart J, Blumenstein M, Haas infiltrating cells in human cancer: On the possible role of CD161
macrophages in antitumor cytotoxicity. Lab Invest 67:166–174,JG: Differential expression of cytokines in human blood monocyte
subpopulations. Blood 79:503–511, 1992 1992
21. Young DA, Lowe LD, Clark SC: Comparison of the effects of13. Nockher WA, Bergmann L, Scherberich JE: Increased soluble
CD14 serum levels and altered CD 14 expression of peripheral IL-3, granulocyte-macrophage colony-stimulating factor, and mac-
rophage colony-stimulating factor in supporting monocyte differ-blood monocytes in HIV-infected patients. Clin Exp Immunol
98:369–374, 1994 entiation in culture: Analysis of macrophage antibody-dependent
cellular cytotoxicity. J Immunol 145:607–615, 199014. Shmid I, Baldwin GC, Jacobs EL, Isacescu V, Neagos N, Giorgi
